BCR-ABL activity measured by 50% inhibitory concentration for
imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of
patients with chronic myeloid leukemia does not predict
treatment response.

J 2012

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ et. al.

Basic information

Original name

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Authors

ŠIMARA, Pavel (203 Czech Republic, belonging to the institution), Martina PETERKOVÁ (203 Czech Republic, belonging to the institution), Stanislav STEJSKAL (203 Czech Republic, belonging to the institution), Michaela POTĚŠILOVÁ (203 Czech Republic, belonging to the institution), Irena KRONTORÁD KOUTNÁ (203 Czech Republic, guarantor, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Filip RÁZGA (703 Slovakia, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Leukemia & lymphoma, England, Informa Healthcare, 2012, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.301

RIV identification code

RIV/00216224:14330/12:00059688

Organization unit

Faculty of Informatics

DOI

http://dx.doi.org/10.3109/10428194.2012.656104

UT WoS

000306566000035

Keywords in English

p-CrkL; chronic myeloid leukemia; imatinib

Abstract

V originále

In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.

Links

GBP302/12/G157, research and development project

Name: Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii

Investor: Czech Science Foundation

MSM0021622430, plan (intention)

Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies

Citovat

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma. England: Informa Healthcare, 2012, vol. 53, No 8, p. 1627-1629. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.656104.

@article{979222,
   author = {Šimara, Pavel and Peterková, Martina and Stejskal, Stanislav and Potěšilová, Michaela and Krontorád Koutná, Irena and Ráčil, Zdeněk and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Mayer, Jiří},
   article_location = {England},
   article_number = {8},
   doi = {http://dx.doi.org/10.3109/10428194.2012.656104},
   keywords = {p-CrkL; chronic myeloid leukemia; imatinib},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & lymphoma},
   title = {BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/22233112},
   volume = {53},
   year = {2012}
}

TY  - JOUR
ID  - 979222
AU  - Šimara, Pavel - Peterková, Martina - Stejskal, Stanislav - Potěšilová, Michaela - Krontorád Koutná, Irena - Ráčil, Zdeněk - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Mayer, Jiří
PY  - 2012
TI  - BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
JF  - Leukemia & lymphoma
VL  - 53
IS  - 8
SP  - 1627-1629
EP  - 1627-1629
PB  - Informa Healthcare
SN  - 10428194
KW  - p-CrkL
KW  - chronic myeloid leukemia
KW  - imatinib
UR  - http://www.ncbi.nlm.nih.gov/pubmed/22233112
L2  - http://www.ncbi.nlm.nih.gov/pubmed/22233112
N2  - In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
ER  -

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and Jiří MAYER. BCR-ABL activity measured by 50\%{} inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. \textit{Leukemia \&{} lymphoma}. England: Informa Healthcare, 2012, vol.~53, No~8, p.~1627-1629. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.656104.

Detailed Information on Publication Record